医学
伊立替康
福尔菲里
帕尼单抗
内科学
氟尿嘧啶
临床终点
结直肠癌
克拉斯
无进展生存期
危险系数
胃肠病学
外科
临床研究阶段
肿瘤科
随机对照试验
化疗
癌症
置信区间
作者
Antonio Avallone,Francesco Giuliani,Alfonso De Stefano,Giuseppe Santabarbara,Guglielmo Nasti,Vincenzo Montesarchio,Gerardo Rosati,Antonino Cassata,Silvana Leo,Carmela Romano,Emiliano Tamburini,Lucrezia Silvestro,Claudio Lotesoriere,Anna Giulia Nappi,Daniele Santini,Antonella Petrillo,Alfredo Colombo,Antonio Febbraro,Alessandra Leone,Francesco Mannavola
摘要
PURPOSE To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable RAS / BRAF wild-type (wt) metastatic colorectal cancer (mCRC). PATIENTS AND METHODS IMPROVE (ClinicalTrials.gov identifier: NCT04425239 ) was an open-label, multicenter, randomized phase II noncomparative trial. Patients with unresectable RAS / BRAF wt mCRC were randomly assigned (1:1) to receive FOLFIRI plus PAN continuously until progression (arm A) or intermittently, with treatment-free intervals (arm B) until progression on treatment, toxicity, or death. The primary end point was progression-free survival on treatment (PFSot) at 12 months. Assuming a null hypothesis of median PFSot time ≤7 months and target PFSot ≥10 months, 65 patients per arm were needed to achieve 80% power and 10% type I error, according to the binomial test. RESULTS Between May 2018 and June 2021, 69 patients were randomly assigned to arm A and 68 to arm B. The median number of treatment cycles was 13 in arm A and 16 in arm B. At a median follow-up of 43.2 months (IQR, 35.0-50.5), median PFSot was 11.2 and 17.5 months with 12-month PFSot rates of 45.7% and 58.5%, for arms A and B, respectively. The overall response rates were 68.1% and 61.2%, and median overall survival rates were 36.3 and 35.1 months in arms A and B, respectively. The overall rate of grade >2 skin PAN-related adverse events was 30.3% in arm A and 17.9% in arm B. CONCLUSION Intermittent FOLFIRI plus PAN after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI